Wells Fargo & Co. upgraded shares of C.R. Bard Inc. (NYSE:BCR) from a market perform rating to an outperform rating in a research note released on Friday.

BCR has been the subject of several other research reports. Bank of America Corp. downgraded shares of C.R. Bard from a buy rating to a neutral rating in a research note on Friday, July 8th. Barclays PLC upped their target price on shares of C.R. Bard from $212.00 to $224.00 and gave the company an equal weight rating in a research note on Tuesday, May 24th. Jefferies Group upped their target price on shares of C.R. Bard from $215.00 to $237.00 and gave the company a hold rating in a research note on Wednesday, July 27th. JPMorgan Chase & Co. upped their target price on shares of C.R. Bard from $214.00 to $225.00 and gave the company a neutral rating in a research note on Wednesday, July 27th. Finally, Leerink Swann reaffirmed a hold rating on shares of C.R. Bard in a research note on Wednesday, May 25th. Thirteen research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. C.R. Bard has a consensus rating of Hold and an average price target of $233.00.

C.R. Bard (NYSE:BCR) opened at 227.96 on Friday. The company has a market cap of $16.74 billion, a P/E ratio of 53.01 and a beta of 0.57. The stock’s 50 day moving average is $220.20 and its 200-day moving average is $217.61. C.R. Bard has a 12-month low of $172.21 and a 12-month high of $239.43.

C.R. Bard (NYSE:BCR) last issued its earnings results on Tuesday, July 26th. The company reported $2.54 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.47 by $0.07. C.R. Bard had a net margin of 9.20% and a return on equity of 48.43%. The firm earned $931.50 million during the quarter, compared to the consensus estimate of $915.22 million. During the same quarter in the prior year, the firm earned $2.27 earnings per share. The business’s quarterly revenue was up 8.3% on a year-over-year basis. Analysts predict that C.R. Bard will post $10.17 earnings per share for the current fiscal year.

In other news, VP John A. Deford sold 7,928 shares of the stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $221.06, for a total value of $1,752,563.68. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Betty D. Larson sold 4,032 shares of the stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $225.33, for a total transaction of $908,530.56. Following the completion of the transaction, the vice president now directly owns 10,298 shares in the company, valued at $2,320,448.34. The disclosure for this sale can be found here. Company insiders own 0.97% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Standard Life Investments LTD bought a new position in shares of C.R. Bard during the second quarter valued at $241,642,000. Norges Bank bought a new position in shares of C.R. Bard during the fourth quarter valued at $123,663,000. JPMorgan Chase & Co. raised its position in shares of C.R. Bard by 353.4% in the first quarter. JPMorgan Chase & Co. now owns 667,533 shares of the company’s stock valued at $135,290,000 after buying an additional 520,319 shares during the last quarter. Fundsmith LLP raised its position in shares of C.R. Bard by 24.7% in the second quarter. Fundsmith LLP now owns 2,197,626 shares of the company’s stock valued at $516,220,000 after buying an additional 435,595 shares during the last quarter. Finally, Bank of Montreal Can bought a new position in shares of C.R. Bard during the second quarter valued at $96,292,000. 87.90% of the stock is currently owned by institutional investors.

About C.R. Bard

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

5 Day Chart for NYSE:BCR

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.